Focus on Healthy China, Theory of Network Disease (First Health Report, Beijing, Intern Reporter Li Shuqing)
On March 27, Professor Wu Yiling, an academician of the Chinese Academy of Engineering, introduced a series of achievements in theory, mechanism and clinical aspects around the project of "Construction of Context Theory of Traditional Chinese Medicine and Its Guidance for the Prevention and Treatment of Microvascular Lesions".
Recently, the project of "Construction of Context Theory of Traditional Chinese Medicine to Promote the Prevention and Treatment of Microvascular Lesions" was selected as a landmark scientific and technological achievement of traditional Chinese medicine in the new era (2012-2022), ranking first in the first category of "the formation of new theories and new disciplines of traditional Chinese medicine", and the project won the first prize of the National Science and Technology Progress Award.
The conference on the construction of the theoretical system of network disease and its transformation and application was held in Beijing
Academician Wu Yiling gave a report entitled "Construction of Theoretical System of Network Disease and Its Transformation and Application" at the meeting
The vein theory provides original theoretical guidance for solving the problem of microvascular lesions
Microangiopathy is a systemic lesion of the whole body, a difficult problem in the international medical community, an important factor in the occurrence and development of major diseases such as cardiovascular and cerebrovascular diseases, diabetes, etc., and a key factor that is difficult to improve the clinical efficacy of these diseases.
"Microcirculation" proposes that the essence of cardiovascular disease is microcirculation disorder, which is the main cause and aggravating factor of cardiovascular disease. Academician Wu Yiling pointed out that "pulse" is called blood vein in traditional Chinese medicine, which is the channel that runs the blood, and is anatomically identical with the blood vessels of Western medicine. The vein is the branch of the blood vessel, including the microvascularity and microcirculation.
Through the two 973 projects, a new theoretical doctrine - the theory of vein was constructed to guide the prevention and treatment of cardiovascular and cerebrovascular diseases and diabetic vascular complications, and the core theory of the theory of vein was put forward - the theory of camp and health, the clinical syndrome differentiation and diagnosis criteria of vascular lesions were established, and the medication rules for the treatment of vascular lesions were put forward by regulating the qi and blood of the camp and health. Under the guidance of the theory of vein, Tongxinluo Capsule for the treatment of ischemic cardiovascular and cerebrovascular diseases, Ginseng Song Yangxin Capsule for the treatment of arrhythmia, and Qili Qiangxin Capsule for the treatment of chronic heart failure have been developed.
The expert group of the National 973 Program commented: "The theory of the vein theory has formed a new theory to guide the prevention and treatment of major diseases of microangiopathy, which is an original achievement of academic research in traditional Chinese medicine. ”
Protection of microvascular endothelial cells is a core mechanism in the treatment of microangiopathies
"Our more than 10 research groups began to study in 2005 and analyzed more than 33,000 research data, revealing for the first time that microangiopathy is a complex network lesion with microvascular endothelial cell damage as the core and initiating factor, blood components and neurohumoral humoral involvement, organ tissue cell structure and function damage, and multi-dimensional spatio-temporal dynamic evolution. Academician Wu Yiling said.
Experiments have confirmed that the protection of microvascularity is a common mechanism for the treatment of major clinical diseases of the heart, brain (sugar) and kidney, and the protection of microvascular endothelial cells is the core mechanism to solve the problem of microvascular lesions. Because of the protection of microvascularity, the tissue blood perfusion of the heart, brain, and kidney microcirculation is improved, thereby alleviating the clinical condition.
Evidence-based studies have confirmed that Tongluo drugs can solve major clinical problems in cardiovascular and cerebrovascular diseases
Academician Wu Yiling said: "We have carried out a lot of evidence-based research on three Chinese patent medicines for the treatment of cardiovascular and cerebrovascular diseases: Tongxinluo Capsule, Ginseng Song Yangxin Capsule, and Qili Qiangxin Capsule. ”
Led by Professor Yang Yuejin and participated by 124 hospitals across the country, the randomized, double-blind, placebo-controlled Tongxinluo clinical evidence-based study results showed that Tongxinluo significantly reduced the risk of major adverse cardiovascular and cerebrovascular events by 36% and cardiovascular death by 30% at 30 days; It was published in the Journal of the American Medical Association (JAMA) and was awarded the Top Ten Academic Advances in Traditional Chinese Medicine in 2023, the Top Ten Medical Research in China, and the Top Ten Highlights in the Field of Cardiology in China, becoming a milestone breakthrough in the field of Chinese medicine going international in the past century.
Previous studies have also shown that Tongxinluo has a triple protective effect of blood, blood vessels, and ischemic tissue. A clinical study of 1,212 cases of "Tongxinluo intervention for carotid artery plaque" showed that Tongxinluo can stabilize vulnerable plaques and reduce the incidence of "cardiovascular events". The results of a 2007 clinical study of "Tongxinluo in the treatment of ischemic stroke" showed that Tongxinluo can significantly improve the self-care ability and neurological function of patients with acute cerebral infarction.
Academician Wu Yiling introduced that the theory of vein guided the treatment of arrhythmia and developed Ginseng Song Yangxin Capsule, which has the prominent feature of "fast and slow treatment, integrated regulation". A number of evidence-based medical studies have been carried out around Ginseng Song Yangxin Capsule, and good results have been obtained.
A series of scientific research results have also been made in guiding the treatment of chronic heart failure. At the 2023 Annual Meeting of the European Society of Cardiology, the results of the "Evaluation Study of the Composite Endpoint Event of Qili Qiangxin Capsule in the Treatment of Chronic Heart Failure" were announced. The study used randomized, double-blind, placebo-controlled, multi-center clinical research methods to complete the clinical evidence-based study of 3119 cases of Qili qiangxin on chronic heart failure composite endpoint events. The results showed that the risk of the main composite endpoint of chronic heart failure was reduced by 22% compared with the control group, which provided effective therapeutic drugs for improving the long-term prognosis of chronic heart failure. The study was awarded the "Top 10 Highlights in the Field of Cardiology in China in 2023" and has had a significant international impact.
(Editor in charge: Mint)